SLC16A3 and atherosclerosis: Clinical sample analysis also revealed a pronounced increase in MCT4 in atherosclerotic plaques, and experiments using human peripheral blood mononuclear cells (PBMCs) further validated that H3K18la may attenuate inflammation and reverse atherosclerosis through the above mechanisms [82].